Angelicin
Based on 11 publication(s) in Google Scholar
Angelicin is a furanocoumarin compound that functions as an inhibitor of NF-κB and MAPK signaling pathways, exhibiting anti-inflammatory, antiviral, and antitumor activities. It suppresses the lytic replication of γ-herpesviruses, such as MHV-68, early during viral infection, potentially inhibiting RTA gene expression (IC50=28.95 μM). Angelicin also mitigates inflammation by inhibiting the phosphorylation and nuclear translocation of NF-κB, and the phosphorylation of p38 and JNK. Furthermore, it induces apoptosis in neuroblastoma cells by downregulating anti-apoptotic proteins like Bcl-2, Bcl-xL, and Mcl-1, while activating caspase-9 and caspase-3.
For research use only. We do not sell to patients.
- Purity: 99.98%
- CAS No.: 523-50-2
- Formula: C11H6O3
- Molecular Weight:186.16
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Angelicin
More- Biomed Pharmacother. 2023 May:161:114462. [Abstract]
- Chem Biol Interact. 2024 Jul 3:111133. [Abstract]
- J Ethnopharmacol. 2022 Nov 15:298:115593. [Abstract]
- Front Pharmacol. 2021 Jun 9:12:669213. [Abstract]
- Arthritis Res Ther. 2021 Sep 17;23(1):243. [Abstract]
- ACS Omega. 2025 Aug 21;10(34):39192-39202. [Abstract]
- Pestic Biochem Physiol. 2025 Dec:215:106655. [Abstract]
- Metabolites. 2022 Dec 20;13(1):3. [Abstract]
- J Orthop Surg Res. 2023 Apr 17;18(1):304. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- bioRxiv. 2023 Jun 15.
-
Cell Proliferation/Viability Assay
-
Apoptosis Analysis
-
WB
-
RT-PCR
-
ELISA
All Caspase Isoforms
More
Biological Activity
|
Caspase-9 |
Caspase-3 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>10 μM
Compound: 21
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 25710081] |
| HL-60 | GI50 |
1.2 μM
Compound: Ang
|
Photocytotoxicity against human HL60 cells assessed as growth inhibition at 2.5 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay
Photocytotoxicity against human HL60 cells assessed as growth inhibition at 2.5 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay
|
[PMID: 26295175] |
| HL-60 | IC50 |
0.9 μM
Compound: 2, ANG
|
Photocytotoxicity against human HL-60 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
Photocytotoxicity against human HL-60 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
|
[PMID: 18951030] |
| HL-60 | IC50 |
0.9 μM
Compound: Ang
|
Phototoxicity in 3.75 J/cm'2 UV-A irradiated human HL60 cells after 72 hrs by MTT assay
Phototoxicity in 3.75 J/cm'2 UV-A irradiated human HL60 cells after 72 hrs by MTT assay
|
[PMID: 21397509] |
| HL-60 | IC50 |
0.9 μM
Compound: Angelicin
|
Cytotoxicity against HL-60 (human fibrosarcoma) cell line at 3.2 joule/cm**2 UVA dose
Cytotoxicity against HL-60 (human fibrosarcoma) cell line at 3.2 joule/cm**2 UVA dose
|
[PMID: 15837311] |
| HL-60 | IC50 |
1.2 μM
Compound: 2, ANG
|
Photocytotoxicity against human HL-60 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
Photocytotoxicity against human HL-60 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
|
[PMID: 18951030] |
| HL-60 | IC50 |
1.2 μM
Compound: Ang
|
Phototoxicity in 2.5 J/cm'2 UV-A irradiated human HL60 cells after 72 hrs by MTT assay
Phototoxicity in 2.5 J/cm'2 UV-A irradiated human HL60 cells after 72 hrs by MTT assay
|
[PMID: 21397509] |
| HL-60 | IC50 |
1.2 μM
Compound: Angelicin
|
Cytotoxicity against HL-60 (human fibrosarcoma) cell line at 2.5 joule/cm**2 UVA dose
Cytotoxicity against HL-60 (human fibrosarcoma) cell line at 2.5 joule/cm**2 UVA dose
|
[PMID: 15837311] |
| HL-60 | IC50 |
16 μM
Compound: 2
|
Cytotoxicity against HL-60 (human fibrosarcoma) cell line; Range 0.4-16 uM
Cytotoxicity against HL-60 (human fibrosarcoma) cell line; Range 0.4-16 uM
|
[PMID: 15837311] |
| HT-1080 | IC50 |
15.7 μM
Compound: 2, ANG
|
Photocytotoxicity against human HT1080 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
Photocytotoxicity against human HT1080 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
|
[PMID: 18951030] |
| HT-1080 | IC50 |
15.7 μM
Compound: Angelicin
|
Inhibition of cell growth after irradiation at UVA dose of 2.6 J/cmE-2 in HT1080 human fibrosarcoma cell line
Inhibition of cell growth after irradiation at UVA dose of 2.6 J/cmE-2 in HT1080 human fibrosarcoma cell line
|
[PMID: 12873520] |
| HT-1080 | IC50 |
2.5 μM
Compound: Angelicin
|
Inhibition of cell growth after irradiation at UVA dose of 6.5 J/cmE-2 in HT1080 human fibrosarcoma cell line
Inhibition of cell growth after irradiation at UVA dose of 6.5 J/cmE-2 in HT1080 human fibrosarcoma cell line
|
[PMID: 12873520] |
| HT-1080 | IC50 |
2.6 μM
Compound: 2, ANG
|
Photocytotoxicity against human HT1080 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
Photocytotoxicity against human HT1080 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
|
[PMID: 18951030] |
| HT-1080 | IC50 |
2.6 μM
Compound: Angelicin
|
Inhibition of cell growth after irradiation at UVA dose of 3.2 J/cmE-2 in HT1080 human fibrosarcoma cell line
Inhibition of cell growth after irradiation at UVA dose of 3.2 J/cmE-2 in HT1080 human fibrosarcoma cell line
|
[PMID: 12873520] |
| Jurkat | GI50 |
1 μM
Compound: Ang
|
Photocytotoxicity against human Jurkat cells assessed as growth inhibition at 2.5 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay
Photocytotoxicity against human Jurkat cells assessed as growth inhibition at 2.5 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay
|
[PMID: 26295175] |
| Jurkat | IC50 |
>20 μM
Compound: 2, Ang
|
Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay
Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay
|
[PMID: 19230658] |
| Jurkat | IC50 |
0.9 μM
Compound: 2, ANG
|
Photocytotoxicity against human JURKAT cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
Photocytotoxicity against human JURKAT cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
|
[PMID: 18951030] |
| Jurkat | IC50 |
0.9 μM
Compound: 2, Ang
|
Phototoxicity against human Jurkat cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay
Phototoxicity against human Jurkat cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay
|
[PMID: 19230658] |
| Jurkat | IC50 |
0.9 μM
Compound: Ang
|
Phototoxicity against human Jurkat cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay
Phototoxicity against human Jurkat cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay
|
[PMID: 20627596] |
| Jurkat | IC50 |
0.9 μM
Compound: Ang
|
Phototoxicity in 3.75 J/cm'2 UV-A irradiated human Jurkat cells after 72 hrs by MTT assay
Phototoxicity in 3.75 J/cm'2 UV-A irradiated human Jurkat cells after 72 hrs by MTT assay
|
[PMID: 21397509] |
| Jurkat | IC50 |
1 μM
Compound: Ang
|
Phototoxicity against human Jurkat cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay
Phototoxicity against human Jurkat cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay
|
[PMID: 20627596] |
| Jurkat | IC50 |
1 μM
Compound: Ang
|
Phototoxicity in 2.5 J/cm'2 UV-A irradiated human Jurkat cells after 72 hrs by MTT assay
Phototoxicity in 2.5 J/cm'2 UV-A irradiated human Jurkat cells after 72 hrs by MTT assay
|
[PMID: 21397509] |
| K562 | IC50 |
>10 μM
Compound: 21
|
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 25710081] |
| K562 | IC50 |
>20 μM
Compound: 2, Ang
|
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 19230658] |
| K562 | IC50 |
1 μM
Compound: Ang
|
Phototoxicity against human K562 cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay
Phototoxicity against human K562 cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay
|
[PMID: 20627596] |
| K562 | IC50 |
1.2 μM
Compound: Ang
|
Phototoxicity against human K562 cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay
Phototoxicity against human K562 cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay
|
[PMID: 20627596] |
| LoVo | GI50 |
1.11 μM
Compound: Ang
|
Photocytotoxicity against human LoVo cells assessed as growth inhibition at 3.75 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay
Photocytotoxicity against human LoVo cells assessed as growth inhibition at 3.75 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay
|
[PMID: 26295175] |
| LoVo | GI50 |
4 μM
Compound: Ang
|
Photocytotoxicity against human LoVo cells assessed as growth inhibition at 2.5 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay
Photocytotoxicity against human LoVo cells assessed as growth inhibition at 2.5 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay
|
[PMID: 26295175] |
| LoVo | IC50 |
>20 μM
Compound: 2, Ang
|
Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
|
[PMID: 19230658] |
| LoVo | IC50 |
0.8 μM
Compound: Angelicin
|
Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 6.5 joule/cm**2 UVA dose
Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 6.5 joule/cm**2 UVA dose
|
[PMID: 15837311] |
| LoVo | IC50 |
0.9 μM
Compound: 2, ANG
|
Photocytotoxicity against human LoVo cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
Photocytotoxicity against human LoVo cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
|
[PMID: 18951030] |
| LoVo | IC50 |
0.9 μM
Compound: 2, Ang
|
Phototoxicity against human LoVo cells exposed to irradiation with 3.75 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay
Phototoxicity against human LoVo cells exposed to irradiation with 3.75 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay
|
[PMID: 19230658] |
| LoVo | IC50 |
0.9 μM
Compound: Angelicin
|
Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 3.2 joule/cm**2 UVA dose
Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 3.2 joule/cm**2 UVA dose
|
[PMID: 15837311] |
| LoVo | IC50 |
1.1 μM
Compound: Ang
|
Phototoxicity in 3.75 J/cm'2 UV-A irradiated human LoVo cells after 72 hrs by MTT assay
Phototoxicity in 3.75 J/cm'2 UV-A irradiated human LoVo cells after 72 hrs by MTT assay
|
[PMID: 21397509] |
| LoVo | IC50 |
1.5 μM
Compound: Ang
|
Phototoxicity against human LoVo cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay
Phototoxicity against human LoVo cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay
|
[PMID: 20627596] |
| LoVo | IC50 |
1.6 μM
Compound: 2, ANG
|
Photocytotoxicity against human LoVo cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
Photocytotoxicity against human LoVo cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
|
[PMID: 18951030] |
| LoVo | IC50 |
1.6 μM
Compound: 2, Ang
|
Phototoxicity against human LoVo cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay
Phototoxicity against human LoVo cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay
|
[PMID: 19230658] |
| LoVo | IC50 |
1.6 μM
Compound: Angelicin
|
Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 2.5 joule/cm**2 UVA dose
Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 2.5 joule/cm**2 UVA dose
|
[PMID: 15837311] |
| LoVo | IC50 |
16 μM
Compound: 2
|
Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line; Range 0.4-16 uM
Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line; Range 0.4-16 uM
|
[PMID: 15837311] |
| LoVo | IC50 |
3.6 μM
Compound: Ang
|
Phototoxicity against human LoVo cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay
Phototoxicity against human LoVo cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay
|
[PMID: 20627596] |
| LoVo | IC50 |
4 μM
Compound: Ang
|
Phototoxicity in 2.5 J/cm'2 UV-A irradiated human LoVo cells after 72 hrs by MTT assay
Phototoxicity in 2.5 J/cm'2 UV-A irradiated human LoVo cells after 72 hrs by MTT assay
|
[PMID: 21397509] |
| MCF7 | GI50 |
1.5 μM
Compound: Ang
|
Photocytotoxicity against human MCF7 cells assessed as growth inhibition at 3.75 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay
Photocytotoxicity against human MCF7 cells assessed as growth inhibition at 3.75 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay
|
[PMID: 26295175] |
| MCF7 | GI50 |
4.42 μM
Compound: Ang
|
Photocytotoxicity against human MCF7 cells assessed as growth inhibition at 2.5 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay
Photocytotoxicity against human MCF7 cells assessed as growth inhibition at 2.5 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay
|
[PMID: 26295175] |
| MCF7 | IC50 |
1.5 μM
Compound: Ang
|
Phototoxicity against human MCF7 cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay
Phototoxicity against human MCF7 cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay
|
[PMID: 20627596] |
| MCF7 | IC50 |
1.5 μM
Compound: Ang
|
Phototoxicity in 3.75 J/cm'2 UV-A irradiated human MCF7 cells after 72 hrs by MTT assay
Phototoxicity in 3.75 J/cm'2 UV-A irradiated human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 21397509] |
| MCF7 | IC50 |
4.4 μM
Compound: Ang
|
Phototoxicity against human MCF7 cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay
Phototoxicity against human MCF7 cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay
|
[PMID: 20627596] |
| MCF7 | IC50 |
4.4 μM
Compound: Ang
|
Phototoxicity in 2.5 J/cm'2 UV-A irradiated human MCF7 cells after 72 hrs by MTT assay
Phototoxicity in 2.5 J/cm'2 UV-A irradiated human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 21397509] |
| NCTC-2544 | IC50 |
>20 μM
Compound: 2, Ang
|
Cytotoxicity against human NCTC-2544 cells after 72 hrs by MTT assay
Cytotoxicity against human NCTC-2544 cells after 72 hrs by MTT assay
|
[PMID: 19230658] |
| NCTC-2544 | IC50 |
0.9 μM
Compound: Ang
|
Phototoxicity against human sNCTC-2544 cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay
Phototoxicity against human sNCTC-2544 cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay
|
[PMID: 20627596] |
| NCTC-2544 | IC50 |
0.9 μM
Compound: Ang
|
Phototoxicity in 3.75 J/cm'2 UV-A irradiated human NCTC-2544 cells after 72 hrs by MTT assay
Phototoxicity in 3.75 J/cm'2 UV-A irradiated human NCTC-2544 cells after 72 hrs by MTT assay
|
[PMID: 21397509] |
| NCTC-2544 | IC50 |
1.5 μM
Compound: 2, ANG
|
Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
|
[PMID: 18951030] |
| NCTC-2544 | IC50 |
4.2 μM
Compound: 2, ANG
|
Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay
|
[PMID: 18951030] |
| NCTC-2544 | IC50 |
4.2 μM
Compound: 2, Ang
|
Phototoxicity against human NCTC-2544 cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay
Phototoxicity against human NCTC-2544 cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay
|
[PMID: 19230658] |
| NCTC-2544 | IC50 |
4.2 μM
Compound: Ang
|
Phototoxicity against human sNCTC-2544 cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay
Phototoxicity against human sNCTC-2544 cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay
|
[PMID: 20627596] |
| NCTC-2544 | IC50 |
4.2 μM
Compound: Ang
|
Phototoxicity in 2.5 J/cm'2 UV-A irradiated human NCTC-2544 cells after 72 hrs by MTT assay
Phototoxicity in 2.5 J/cm'2 UV-A irradiated human NCTC-2544 cells after 72 hrs by MTT assay
|
[PMID: 21397509] |
Angelicin (30-50 μM; 48 h) induced apoptosis in SH-SY5Y cells, causing downregulation of Bcl-2, Bcl-xL, and Mcl-1 protein expression, and activated the cleavage of caspase-9 and caspase-3, leading to apoptosis[1].
Angelicin (28.95 μM; 48 h) inhibited viral replication in MHV-68-infected BHK21 cells, causing downregulation of viral proteins ORF45 and ORF65 expression, and reduced viral genome replication and RTA mRNA expression[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LPS-induced acute lung injury BALB/c mouse model[3]
-
Dosage:1, 5, 10 mg/kg
-
Administration:ip
-
Result:Reduced the number of inflammatory cells, lung wet-to-dry weight ratio, MPO activity, reduced TNF-α and IL-6 levels, and improved lung tissue pathological changes.
Chemical Information
-
CAS No. 523-50-2
-
Appearance Solid
-
Molecular Weight 186.16
-
Formula C11H6O3
-
Color White to off-white
-
SMILES
O=C1C=CC2=CC=C(OC=C3)C3=C2O1
-
Synonyms
Isopsoralen
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Biomed Pharmacother
Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathway. [Abstract]2023 May:161:114462. PMID: 36933380 -
Chem Biol Interact
Bavachinin, a main compound of Psoraleae Fructus, facilitates GSDMD-mediated pyroptosis and causes hepatotoxicity in mice. [Abstract]2024 Jul 3:111133. PMID: 38969277 -
J Ethnopharmacol
2022 Nov 15:298:115593. PMID: 35973629 -
Front Pharmacol
Angelicin Alleviates Post-Trauma Osteoarthritis Progression by Regulating Macrophage Polarization via STAT3 Signaling Pathway. [Abstract]2021 Jun 9:12:669213. PMID: 34177582
Angelicin purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2021 Jun 9:12:669213. [Abstract]
Effect of angelicin on the cell viability of BMM. The cytotoxic effects of Angelicin (10, 20, 30, 50, 100 μmol/L) were detected at the different concentrations for 24 and 48 h using CCK-8 assay.
Angelicin purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2021 Jun 9:12:669213. [Abstract]
Representative image of apoptosis rate detected by flow cytometry treated with Angelicin (10, 20, 30, 50, 100 μmol/L).
Angelicin purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2021 Jun 9:12:669213. [Abstract]
Western blot analysis of iNOS, Arg-1, STAT3, p-STAT3, and β-actin in BMMs treated with LPS, LPS + Angelicin (ANG) (30 μM), LPS + IL-4/IL-13 + Angelicin + AG490.
Angelicin purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2021 Jun 9:12:669213. [Abstract]
qRT-PCR assay of IL-1β and TNF-α expression in BMMs treated with Angelicin (ANG).(30 μM).
Angelicin purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2021 Jun 9:12:669213. [Abstract]
ELISA for IL-1β and TNF-α concentration from cellular supernatant treated with Angelicin (ANG).(30 μM).
-
Arthritis Res Ther
2021 Sep 17;23(1):243. PMID: 34535196 -
ACS Omega
2025 Aug 21;10(34):39192-39202. PMID: 40918390 -
Pestic Biochem Physiol
Mechanistic insights into chlorogenic acid and caffeic acid as novel juvenile hormone antagonists. [Abstract]2025 Dec:215:106655. PMID: 41162045 -
Metabolites
Coumarins of Lovage Roots (Levisticum officinale W.D.J.Koch): LC-MS Profile, Quantification, and Stability during Postharvest Storage. [Abstract]2022 Dec 20;13(1):3. PMID: 36676932 -
J Orthop Surg Res
A study on the anti-osteoporosis mechanism of isopsoralen based on network pharmacology and molecular experiments. [Abstract]2023 Apr 17;18(1):304. PMID: 37069639 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Solvent & Solubility
DMSO : 33.33 mg/mL (179.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (13.43 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Rahman MA, et al. Angelicin induces apoptosis through intrinsic caspase-dependent pathway in human SH-SY5Y neuroblastoma cells. Mol Cell Biochem. 2012 Oct;369(1-2):95-104. [Content Brief]
[2]. Cho HJ, et al. Antiviral activity of angelicin against gammaherpesviruses. Antiviral Res. 2013 Oct;100(1):75-83. [Content Brief]
[3]. Liu F, et al. Angelicin regulates LPS-induced inflammation via inhibiting MAPK/NF-κB pathways. J Surg Res. 2013 Nov;185(1):300-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.3717 mL | 26.8586 mL | 53.7172 mL | 134.2931 mL |
| 5 mM | 1.0743 mL | 5.3717 mL | 10.7434 mL | 26.8586 mL | |
| 10 mM | 0.5372 mL | 2.6859 mL | 5.3717 mL | 13.4293 mL | |
| 15 mM | 0.3581 mL | 1.7906 mL | 3.5811 mL | 8.9529 mL | |
| 20 mM | 0.2686 mL | 1.3429 mL | 2.6859 mL | 6.7147 mL | |
| 25 mM | 0.2149 mL | 1.0743 mL | 2.1487 mL | 5.3717 mL | |
| 30 mM | 0.1791 mL | 0.8953 mL | 1.7906 mL | 4.4764 mL | |
| 40 mM | 0.1343 mL | 0.6715 mL | 1.3429 mL | 3.3573 mL | |
| 50 mM | 0.1074 mL | 0.5372 mL | 1.0743 mL | 2.6859 mL | |
| 60 mM | 0.0895 mL | 0.4476 mL | 0.8953 mL | 2.2382 mL | |
| 80 mM | 0.0671 mL | 0.3357 mL | 0.6715 mL | 1.6787 mL | |
| 100 mM | 0.0537 mL | 0.2686 mL | 0.5372 mL | 1.3429 mL |